{"description":"Documents matching 'security standards controls must place'","count":10000,"total_pages":50,"next_page_url":"https://www.federalregister.gov/api/v1/documents?conditions%5Bterm%5D=security+standards+controls+must+place&format=json&page=2","results":[{"title":"Request for Information Regarding Security Considerations for Artificial Intelligence Agents","type":"Notice","abstract":"The Center for AI Standards and Innovation (CAISI), housed within the National Institute of Standards and Technology (NIST) at the Department of Commerce, is seeking information and insights from stakeholders on practices and methodologies for measuring and improving the secure development and deployment of artificial intelligence (AI) agent systems. AI agent systems are capable of taking autonomous actions that impact real-world systems or environments, and may be susceptible to hijacking, backdoor attacks, and other exploits. If left unchecked, these security risks may impact public safety, undermine consumer confidence, and curb adoption of the latest AI innovations. We encourage respondents to provide concrete examples, best practices, case studies, and actionable recommendations based on their experience developing and deploying AI agent systems and managing and anticipating their attendant risks. Responses may inform CAISI's work evaluating the security risks associated with various AI capabilities, assessing security vulnerabilities of AI systems, developing evaluation and assessment measurements and methods, generating technical guidelines and best practices to measure and improve the security of AI systems, and other activities related to the security of AI agent systems.","document_number":"2026-00206","html_url":"https://www.federalregister.gov/documents/2026/01/08/2026-00206/request-for-information-regarding-security-considerations-for-artificial-intelligence-agents","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-01-08/pdf/2026-00206.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-00206.pdf?1767793519","publication_date":"2026-01-08","agencies":[{"raw_name":"DEPARTMENT OF COMMERCE","name":"Commerce Department","id":54,"url":"https://www.federalregister.gov/agencies/commerce-department","json_url":"https://www.federalregister.gov/api/v1/agencies/54","parent_id":null,"slug":"commerce-department"},{"raw_name":"National Institute of Standards and Technology","name":"National Institute of Standards and Technology","id":352,"url":"https://www.federalregister.gov/agencies/national-institute-of-standards-and-technology","json_url":"https://www.federalregister.gov/api/v1/agencies/352","parent_id":54,"slug":"national-institute-of-standards-and-technology"}],"excerpts":"identify, and assess <span class=\"match\">security</span> threats, risks, or vulnerabilities? \n i. What methods could be used to detect <span class=\"match\">security</span> incidents after an AI agent system has been deployed? \n ii. How do these align (or differ) from traditional information <span class=\"match\">security</span> practices, including supply chain <span class=\"match\">security</span>? \n iii. What is the maturity of these methods in research and applied use? \n iv. What resources or information would be useful for anticipating, identifying, and assessing <span class=\"match\">security</span> threats, risks, or vulnerabilities? \n (b) Not all <span class=\"match\">security</span> threats, risks, or vulnerabilities"},{"title":"Data Security Requirements for Accessing Confidential Data; Agency Information Collection Activities: Comment Request","type":"Notice","abstract":"The Bureau of Transportation Statistics (BTS) within the Department of Transportation (DOT) invites the general public and other Federal agencies to comment on an existing information collection. BTS collects information from the public to fulfill its data security requirements when providing access to restricted use microdata for the purpose of evidence building. BTS's data security agreements and other paperwork along with the corresponding security protocols allow BTS to maintain careful controls on confidentiality and privacy, as required by law. The purpose of this notice is to allow for 60 days of public comment on the renewal of the data security information collection, prior to submission of the information collection request (ICR) to the Office of Management and Budget (OMB).","document_number":"2026-04735","html_url":"https://www.federalregister.gov/documents/2026/03/11/2026-04735/data-security-requirements-for-accessing-confidential-data-agency-information-collection-activities","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-11/pdf/2026-04735.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-04735.pdf?1773146710","publication_date":"2026-03-11","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"Bureau of Transportation Statistics","name":"Transportation Statistics Bureau","id":495,"url":"https://www.federalregister.gov/agencies/transportation-statistics-bureau","json_url":"https://www.federalregister.gov/api/v1/agencies/495","parent_id":492,"slug":"transportation-statistics-bureau"}],"excerpts":"collection. BTS collects information from the public to fulfill its data <span class=\"match\">security</span> requirements when providing access to restricted use microdata for the purpose of evidence building. BTS's data <span class=\"match\">security</span> agreements and other paperwork along with the corresponding <span class=\"match\">security</span> protocols allow BTS to maintain careful <span class=\"match\">controls</span> on confidentiality and privacy, as required by law. The purpose of this notice is to allow for 60 days of public comment on the renewal of the data <span class=\"match\">security</span> information collection, prior to submission of the information collection"},{"title":"Modernizing Security Requirements","type":"Proposed Rule","abstract":"The U.S. Nuclear Regulatory Commission (NRC) is proposing to revise its regulations to modernize security and fitness-for-duty requirements to enhance efficiency, consistent with Executive Order 14300, \"Ordering the Reform of the Nuclear Regulatory Commission.\" The proposed revisions are intended to reduce regulatory burden, where appropriate, while continuing to provide reasonable assurance that safety and security will be adequately maintained at NRC-licensed facilities.","document_number":"2026-12989","html_url":"https://www.federalregister.gov/documents/2026/06/26/2026-12989/modernizing-security-requirements","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-26/pdf/2026-12989.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12989.pdf?1782391523","publication_date":"2026-06-26","agencies":[{"raw_name":"NUCLEAR REGULATORY COMMISSION","name":"Nuclear Regulatory Commission","id":383,"url":"https://www.federalregister.gov/agencies/nuclear-regulatory-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/383","parent_id":null,"slug":"nuclear-regulatory-commission"}],"excerpts":"Safeguarding of National <span class=\"match\">Security</span> Information and Restricted Data. \n The NRC is proposing to revise 10 CFR part 95, “Facility <span class=\"match\">Security</span> Clearance and Safeguarding of National <span class=\"match\">Security</span> Information and Restricted Data,” to remove requirements that are duplicative and to ensure alignment with 32 CFR part 117, “National Industrial <span class=\"match\">Security</span> Program Operating Manual (NISPOM).” These changes would provide references to the applicable provisions of 32 CFR part 117 for implementation of the National Industrial <span class=\"match\">Security</span> Program.\n \n C. Costs and Benefits \n \n The NRC"},{"title":"Control of Communicable Diseases; Foreign Quarantine","type":"Rule","abstract":"The Centers for Disease Control and Prevention (CDC) within the U.S. Department of Health and Human Services (HHS) issues this interim final rule with request for comments to amend its Foreign Quarantine Regulations. This interim final rule provides a procedure for the Secretary acting through the CDC Director or other delegate to suspend the introduction of persons from designated countries or places, if required, in the interest of public health.","document_number":"2026-10543","html_url":"https://www.federalregister.gov/documents/2026/05/27/2026-10543/control-of-communicable-diseases-foreign-quarantine","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-27/pdf/2026-10543.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10543.pdf?1779480907","publication_date":"2026-05-27","agencies":[{"raw_name":"DEPARTMENT OF HEALTH AND HUMAN SERVICES","name":"Health and Human Services Department","id":221,"url":"https://www.federalregister.gov/agencies/health-and-human-services-department","json_url":"https://www.federalregister.gov/api/v1/agencies/221","parent_id":null,"slug":"health-and-human-services-department"}],"excerpts":"submissions received <span class=\"match\">must</span> include the agency name and docket number or Regulatory Information Number (RIN) for this rulemaking. All comments received will be posted without change to \n http://regulations.gov, \n including any personal information provided. For access to the docket to read background documents or comments received, go to \n http://www.regulations.gov. \n \n \n Any comment that is submitted will be shared with the Department of Homeland <span class=\"match\">Security</span> and the Department of State and will also be made available to the public. Comments <span class=\"match\">must</span> be identified"},{"title":"Schedules of Controlled Substances: Placement of Diphenidine in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing diphenidine (1-(1,2-diphenylethyl)piperidine), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle diphenidine.","document_number":"2026-10380","html_url":"https://www.federalregister.gov/documents/2026/05/26/2026-10380/schedules-of-controlled-substances-placement-of-diphenidine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-26/pdf/2026-10380.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-10380.pdf?1779453913","publication_date":"2026-05-26","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"812(b)(1)(B), when <span class=\"match\">placing</span> a drug or other substance in schedule I, DEA <span class=\"match\">must</span> consider whether the substance has a currently accepted medical use in treatment in the United States. First, DEA looks to whether the drug or substance has FDA approval. When no FDA approval exists, DEA has traditionally applied a five-part test to determine whether a drug or substance has a currently accepted medical use: (1) the drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving"},{"title":"Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam and their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, in schedule I of the Controlled Substances Act. These five substances were temporarily scheduled in an order dated July 26, 2023, and subsequently extended until July 26, 2026, pursuant to an extension published elsewhere in this issue of the Federal Register. This action also enables the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action makes permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle these five specific controlled substances.","document_number":"2026-04112","html_url":"https://www.federalregister.gov/documents/2026/03/02/2026-04112/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-02/pdf/2026-04112.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-04112.pdf?1772199926","publication_date":"2026-03-02","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"currently accepted medical use, DEA has traditionally applied a five-part test to a drug or substance that has not been approved by the FDA: (1) the drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving efficacy; (4) the drug <span class=\"match\">must</span> be accepted by qualified experts; and (5) the scientific evidence <span class=\"match\">must</span> be widely available. \n See Marijuana Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis"},{"title":"Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 4-fluoroamphetamine (4-FA; 1-(4- fluorophenyl)propan-2-amine; para-fluoroamphetamine), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4-fluoroamphetamine.","document_number":"2026-00633","html_url":"https://www.federalregister.gov/documents/2026/01/15/2026-00633/schedules-of-controlled-substances-placement-of-4-fluoroamphetamine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-01-15/pdf/2026-00633.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-00633.pdf?1768398308","publication_date":"2026-01-15","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"exists, DEA has traditionally applied a five-part test to determine whether a drug or substance has a currently accepted medical use: (1) the drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving efficacy; (4) the drug <span class=\"match\">must</span> be accepted by qualified experts; and (5) the scientific evidence <span class=\"match\">must</span> be widely available. \n See Marijuana Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis"},{"title":"Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 5-pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3- b]indol-1-one (other names: CUMYL-PEGACLONE; SGT-151), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle CUMYL-PEGACLONE.","document_number":"2026-09566","html_url":"https://www.federalregister.gov/documents/2026/05/13/2026-09566/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-13/pdf/2026-09566.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-09566.pdf?1778589924","publication_date":"2026-05-13","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"no FDA approval exists, DEA has traditionally applied a five-part test to a drug or substance that has not been approved by the FDA: (1) The drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving efficacy; (4) the drug <span class=\"match\">must</span> be accepted by qualified experts; and (5) the scientific evidence <span class=\"match\">must</span> be widely available. \n See Marijuana Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis"},{"title":"Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places 4-chloromethcathinone (4-CMC, 1-(4-chlorophenyl)- 2-(methylamino)propan-1-one), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 4- chloromethcathinone.","document_number":"2025-20004","html_url":"https://www.federalregister.gov/documents/2025/11/17/2025-20004/schedules-of-controlled-substances-placement-of-4-chloromethcathinone-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-11-17/pdf/2025-20004.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-20004.pdf?1763127920","publication_date":"2025-11-17","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"currently accepted medical use, DEA has traditionally applied a five-part test to a drug or substance that has not been approved by the FDA: i. The drug's chemistry <span class=\"match\">must</span> be known and reproducible; ii. there <span class=\"match\">must</span> be adequate safety studies; iii. there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving efficacy; iv. the drug <span class=\"match\">must</span> be accepted by qualified experts; and v. the scientific evidence <span class=\"match\">must</span> be widely available. \n See Marijuana Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis"},{"title":"Schedules of Controlled Substances: Placement of Tianeptine in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing the substance tianeptine (7-[(3-chloro-6,11-dihydro-6-methyl-5,5- dioxidodibenzo[c,f][1,2]thiazepin-11-yl)amino]heptanoic acid), including its isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of such isomers, esters, ethers, salts, and salts of isomers, esters, and ethers is possible, in schedule I of the Controlled Substances Act. If finalized, this action would impose the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle tianeptine.","document_number":"2026-13821","html_url":"https://www.federalregister.gov/documents/2026/07/08/2026-13821/schedules-of-controlled-substances-placement-of-tianeptine-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-07-08/pdf/2026-13821.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-13821.pdf?1783428319","publication_date":"2026-07-08","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"812(b)(1)(B), when <span class=\"match\">placing</span> a drug or other substance in schedule I, DEA <span class=\"match\">must</span> consider whether the substance has a currently accepted medical use in treatment in the United States. First, DEA looks to whether the drug or substance has FDA approval. When no FDA approval exists, DEA has traditionally applied a five-part test to determine whether a drug or substance has a currently accepted medical use: (1) the drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving"},{"title":"Tanker Security Program","type":"Rule","abstract":"This final rule implements the Tanker Security Program (TSP) and makes certain changes to the TSP interim final rule (IFR) published in the Federal Register on December 7, 2022, in response to public comments received on the IFR, feedback from stakeholders, and MARAD's own experience during initial program administration. The Secretary of Transportation is authorized to establish TSP, comprised of a fleet of active, commercially viable, militarily useful, privately owned product tank vessels of the United States. The TSP Fleet is intended to meet national defense and other security requirements and maintain a United States presence in international commercial shipping. TSP supports the United States maritime industries and workforce to promote national security and economic resilience.","document_number":"2026-12547","html_url":"https://www.federalregister.gov/documents/2026/06/23/2026-12547/tanker-security-program","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-06-23/pdf/2026-12547.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-12547.pdf?1782132312","publication_date":"2026-06-23","agencies":[{"raw_name":"DEPARTMENT OF TRANSPORTATION","name":"Transportation Department","id":492,"url":"https://www.federalregister.gov/agencies/transportation-department","json_url":"https://www.federalregister.gov/api/v1/agencies/492","parent_id":null,"slug":"transportation-department"},{"raw_name":"Maritime Administration","name":"Maritime Administration","id":282,"url":"https://www.federalregister.gov/agencies/maritime-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/282","parent_id":492,"slug":"maritime-administration"}],"excerpts":"vessel details and operational <span class=\"match\">standards</span>: \n (i) Vessel <span class=\"match\">must</span> be a party to the Oil Companies International Marine Forum's Ship Inspection Report (SIRE) System and applicant <span class=\"match\">must</span> provide date of last SIRE report. \n (ii) Applicant <span class=\"match\">must</span> confirm acceptances received and/or retained by the vessel since the last SIRE report. \n (iii) Applicant <span class=\"match\">must</span> confirm that the vessel has not been rejected or refused by any Charterer since the inspections leading to the said SIRE report. \n (iv) Applicant <span class=\"match\">must</span> provide a current Intertanko <span class=\"match\">Standard</span> Tanker Chartering Questionnaire"},{"title":"Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H- indazole-3-carboxamido)butanoate (other name: MDMB-4en-PINACA), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle MDMB-4en-PINACA.","document_number":"2026-08104","html_url":"https://www.federalregister.gov/documents/2026/04/24/2026-08104/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-04-24/pdf/2026-08104.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08104.pdf?1776948327","publication_date":"2026-04-24","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"no FDA approval exists, DEA has traditionally applied a five-part test to a drug or substance that has not been approved by the FDA: (1) The drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving efficacy; (4) the drug <span class=\"match\">must</span> be accepted by qualified experts; and (5) the scientific evidence <span class=\"match\">must</span> be widely available. \n See Marijuana Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis"},{"title":"Quality Control Standards for Automated Valuation Models","type":"Rule","abstract":"The OCC, Board, FDIC, NCUA, CFPB, and FHFA (collectively, the agencies) are adopting a final rule to implement the quality control standards mandated by the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) for the use of automated valuation models (AVMs) by mortgage originators and secondary market issuers in determining the collateral worth of a mortgage secured by a consumer's principal dwelling. Under the final rule, institutions that engage in certain credit decisions or securitization determinations must adopt policies, practices, procedures, and control systems to ensure that AVMs used in these transactions to determine the value of mortgage collateral adhere to quality control standards designed to ensure a high level of confidence in the estimates produced by AVMs; protect against the manipulation of data; seek to avoid conflicts of interest; require random sample testing and reviews; and comply with applicable nondiscrimination laws.","document_number":"2024-16197","html_url":"https://www.federalregister.gov/documents/2024/08/07/2024-16197/quality-control-standards-for-automated-valuation-models","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2024-08-07/pdf/2024-16197.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2024-16197.pdf?1722948312","publication_date":"2024-08-07","agencies":[{"raw_name":"DEPARTMENT OF THE TREASURY","name":"Treasury Department","id":497,"url":"https://www.federalregister.gov/agencies/treasury-department","json_url":"https://www.federalregister.gov/api/v1/agencies/497","parent_id":null,"slug":"treasury-department"},{"raw_name":"Office of the Comptroller of the Currency","name":"Comptroller of the Currency","id":80,"url":"https://www.federalregister.gov/agencies/comptroller-of-the-currency","json_url":"https://www.federalregister.gov/api/v1/agencies/80","parent_id":497,"slug":"comptroller-of-the-currency"},{"raw_name":"FEDERAL RESERVE SYSTEM","name":"Federal Reserve System","id":188,"url":"https://www.federalregister.gov/agencies/federal-reserve-system","json_url":"https://www.federalregister.gov/api/v1/agencies/188","parent_id":null,"slug":"federal-reserve-system"},{"raw_name":"FEDERAL DEPOSIT INSURANCE CORPORATION","name":"Federal Deposit Insurance Corporation","id":164,"url":"https://www.federalregister.gov/agencies/federal-deposit-insurance-corporation","json_url":"https://www.federalregister.gov/api/v1/agencies/164","parent_id":null,"slug":"federal-deposit-insurance-corporation"},{"raw_name":"NATIONAL CREDIT UNION ADMINISTRATION","name":"National Credit Union Administration","id":335,"url":"https://www.federalregister.gov/agencies/national-credit-union-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/335","parent_id":null,"slug":"national-credit-union-administration"},{"raw_name":"Consumer Financial Protection Bureau","name":"Consumer Financial Protection Bureau","id":573,"url":"https://www.federalregister.gov/agencies/consumer-financial-protection-bureau","json_url":"https://www.federalregister.gov/api/v1/agencies/573","parent_id":null,"slug":"consumer-financial-protection-bureau"},{"raw_name":"FEDERAL HOUSING FINANCE AGENCY","name":"Federal Housing Finance Agency","id":174,"url":"https://www.federalregister.gov/agencies/federal-housing-finance-agency","json_url":"https://www.federalregister.gov/api/v1/agencies/174","parent_id":null,"slug":"federal-housing-finance-agency"}],"excerpts":"continue to view quality <span class=\"match\">control</span> <span class=\"match\">standards</span> for AVMs used to make credit decisions relating to loan modifications and other changes to mortgages as important both to safety and soundness and to consumer protection. As discussed below, many institutions have already set up quality <span class=\"match\">control</span> systems for AVMs and have third-party risk management programs in <span class=\"match\">place</span>. For those institutions, existing quality <span class=\"match\">control</span> systems and third-party risk management programs should mitigate the burden of implementing additional quality <span class=\"match\">control</span> <span class=\"match\">standards</span> for AVMs used to modify"},{"title":"Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I","type":"Rule","abstract":"The Drug Enforcement Administration places seven fentanyl- related substances, as identified in this final rule, including their isomers, esters, ethers, salts and salts of isomers, esters and ethers in schedule I of the Controlled Substances Act. The regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle these seven specific controlled substances will continue to apply as a result of this action.","document_number":"2025-18103","html_url":"https://www.federalregister.gov/documents/2025/09/18/2025-18103/schedules-of-controlled-substances-placement-of-seven-specific-fentanyl-related-substances-in","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-09-18/pdf/2025-18103.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-18103.pdf?1758113117","publication_date":"2025-09-18","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"has traditionally applied a five-part test to a drug or substance to determine whether a drug or substance has a currently medical use: i. the drug's chemistry <span class=\"match\">must</span> be known and reproducible; ii. there <span class=\"match\">must</span> be adequate safety studies; iii. there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving efficacy; iv. the drug <span class=\"match\">must</span> be accepted by qualified experts; and v. the scientific evidence <span class=\"match\">must</span> be widely available. Marijuana Scheduling Petition; Denial of Petition; Remand, 57 FR 10499 (Mar. 26, 1992), \n pet. for rev. denied, Alliance for Cannabis Therapeutics"},{"title":"Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I","type":"Rule","abstract":"The Drug Enforcement Administration issues this temporary order to schedule 8-bromo-1-methyl-6-phenyl-4H- benzo[f][1,2,4]triazolo[4,3-a][l, 4]diazepine (commonly known as bromazolam), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers are possible, in schedule I of the Controlled Substances Act. DEA bases this action on a finding that placing bromazolam in schedule I is necessary to avoid an imminent hazard to public safety. This order imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess) or propose to handle these substances.","document_number":"2026-05064","html_url":"https://www.federalregister.gov/documents/2026/03/16/2026-05064/schedules-of-controlled-substances-temporary-placement-of-bromazolam-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-16/pdf/2026-05064.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-05064.pdf?1773405915","publication_date":"2026-03-16","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"exists, DEA has traditionally applied a five-part test to determine whether a drug or substances has a currently accepted medical use: (1) The drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving efficacy; (4) the drug <span class=\"match\">must</span> be accepted by qualified experts; and (5) the scientific evidence <span class=\"match\">must</span> be widely available. \n See Marijuana Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis"},{"title":"Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing the substance CUMYL-PEGACLONE (SGT-151; 5-pentyl-2-(2-phenylpropan-2- yl)pyrido[4,3-b]indol-1-one), including its salts, isomers (including optical, positional, and geometric isomers), and salts of isomers, in schedule I of the Controlled Substances Act. CUMYL-PEGACLONE was temporarily scheduled in an order dated December 12, 2023. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle CUMYL-PEGACLONE.","document_number":"2025-22495","html_url":"https://www.federalregister.gov/documents/2025/12/11/2025-22495/schedules-of-controlled-substances-placement-of-cumyl-pegaclone-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-12-11/pdf/2025-22495.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-22495.pdf?1765374317","publication_date":"2025-12-11","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"when <span class=\"match\">placing</span> a drug or other substance in schedule I of the CSA, DEA <span class=\"match\">must</span> consider whether the substance has a currently accepted medical use in treatment in the United States. First, DEA looks to whether the drug or substance has FDA approval. When no FDA approval exists, DEA has traditionally applied a five-part test to determine whether a drug or substances has a currently accepted medical use: (1) the drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies"},{"title":"Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I","type":"Rule","abstract":"With the issuance of this final rule, the Drug Enforcement Administration places substance 3-methoxyphencyclidine (1-(1-(3- methoxyphenyl)cyclohexyl)piperidine; 3-MeO-PCP), including its salts, isomers, and salts of isomers, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. This action imposes the regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, reverse distribute, import export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle 3-MeO-PCP.","document_number":"2026-05618","html_url":"https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-03-23/pdf/2026-05618.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-05618.pdf?1774010717","publication_date":"2026-03-23","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"when <span class=\"match\">placing</span> a drug or other substance in schedule I of the CSA, DEA <span class=\"match\">must</span> consider whether the substance has a currently accepted medical use in treatment in the United States. First, DEA looks to whether the drug or substance has FDA approval. When no FDA approval exists, DEA has traditionally applied a five-part test to determine whether a drug or substance has a currently accepted medical use: (1) the drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies"},{"title":"Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (other name: MDMB-4en-PINACA), including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible, in schedule I of the Controlled Substances Act. This action is being taken, in part, to enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research, conduct instructional activities or chemical analysis with, or possess) or propose to handle MDMB-4en-PINACA.","document_number":"2025-19348","html_url":"https://www.federalregister.gov/documents/2025/10/02/2025-19348/schedules-of-controlled-substances-placement-of-mdmb-4en-pinaca-in-schedule-i","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-10-02/pdf/2025-19348.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-19348.pdf?1759322729","publication_date":"2025-10-02","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"be known and reproducible; ii. there <span class=\"match\">must</span> be adequate safety studies; iii. there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving efficacy; iv. the drug <span class=\"match\">must</span> be accepted by qualified experts; and v. the scientific evidence <span class=\"match\">must</span> be widely available. See \n Marijuana Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis Therapeutics \n v. \n Drug Enforcement Admin., \n 15 F.3d 1131, 1135 (D.C. Cir. 1994). DEA and HHS applied the traditional five-part test for currently accepted"},{"title":"Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act","type":"Proposed Rule","abstract":"The Drug Enforcement Administration proposes placing clonazolam, diclazepam, etizolam, flualprazolam, and flubromazolam and their salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, as identified in this proposed rule, in schedule I of the Controlled Substances Act. These five substances were temporarily scheduled in an order dated July 26, 2023, and subsequently extended until July 26, 2026, pursuant to an extension published elsewhere in this issue of the Federal Register. This action will also enable the United States to meet its obligations under the 1971 Convention on Psychotropic Substances. If finalized, this action would make permanent the existing regulatory controls and administrative, civil, and criminal sanctions applicable to schedule I controlled substances on persons who handle (manufacture, distribute, import, export, engage in research, conduct instructional activities or chemical analysis, or possess), or propose to handle these five specific controlled substances.","document_number":"2025-14022","html_url":"https://www.federalregister.gov/documents/2025/07/25/2025-14022/schedules-of-controlled-substances-placement-of-clonazolam-diclazepam-etizolam-flualprazolam-and","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2025-07-25/pdf/2025-14022.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2025-14022.pdf?1753361112","publication_date":"2025-07-25","agencies":[{"raw_name":"DEPARTMENT OF JUSTICE","name":"Justice Department","id":268,"url":"https://www.federalregister.gov/agencies/justice-department","json_url":"https://www.federalregister.gov/api/v1/agencies/268","parent_id":null,"slug":"justice-department"},{"raw_name":"Drug Enforcement Administration","name":"Drug Enforcement Administration","id":116,"url":"https://www.federalregister.gov/agencies/drug-enforcement-administration","json_url":"https://www.federalregister.gov/api/v1/agencies/116","parent_id":268,"slug":"drug-enforcement-administration"}],"excerpts":"exists, DEA has traditionally applied a five-part test to determine whether a drug or substances has a currently accepted medical use: (1) the drug's chemistry <span class=\"match\">must</span> be known and reproducible; (2) there <span class=\"match\">must</span> be adequate safety studies; (3) there <span class=\"match\">must</span> be adequate and well-<span class=\"match\">controlled</span> studies proving efficacy; (4) the drug <span class=\"match\">must</span> be accepted by qualified experts; and (5) the scientific evidence <span class=\"match\">must</span> be widely available. \n Marijuana Scheduling Petition; Denial of Petition; Remand, \n 57 FR 10499 (Mar. 26, 1992), pet. for rev. denied, \n Alliance for Cannabis"},{"title":"Staff Report on the Definitions of “Security-Based Swap Dealer” and “Major Security-Based Swap Participant”","type":"Notice","abstract":"The Securities and Exchange Commission directed staff to prepare and is now publishing a report examining the effect and application of the definitions of \"security-based swap dealer\" and \"major security-based swap participant.\" Those definitions include an exception from designation as a security-based swap dealer for an entity that engages in a de minimis quantity of security-based swap dealing, as well as separate thresholds below which an entity would not become a major security-based swap participant. As provided in the Commission's rules, nine months after publication of this report and after considering any public comments received, the Commission may by order either terminate the phase-in period for the de minimis thresholds, thereby allowing thresholds of $3 billion for credit default swaps that constitute security-based swaps and $150 million for non-credit default swaps that constitute security-based swaps to take effect and replace the current phase-in thresholds of $8 billion and $400 million, respectively, or propose different thresholds through rulemaking; however, the Commission has issued an order providing a temporary exemption that has the effect of continuing to apply the phase-in thresholds of $8 billion and $400 million until May 8, 2028. The public is invited to comment on all aspects of this report, which may inform the Commission's consideration of potential changes to the de minimis exception and the rules further defining the terms \"security-based swap dealer\" and \"major security-based swap participant.\"","document_number":"2026-08558","html_url":"https://www.federalregister.gov/documents/2026/05/04/2026-08558/staff-report-on-the-definitions-of-security-based-swap-dealer-and-major-security-based-swap","pdf_url":"https://www.govinfo.gov/content/pkg/FR-2026-05-04/pdf/2026-08558.pdf","public_inspection_pdf_url":"https://public-inspection.federalregister.gov/2026-08558.pdf?1777639507","publication_date":"2026-05-04","agencies":[{"raw_name":"SECURITIES AND EXCHANGE COMMISSION","name":"Securities and Exchange Commission","id":466,"url":"https://www.federalregister.gov/agencies/securities-and-exchange-commission","json_url":"https://www.federalregister.gov/api/v1/agencies/466","parent_id":null,"slug":"securities-and-exchange-commission"}],"excerpts":"for comment. \n \n \n SUMMARY: \n The <span class=\"match\">Securities</span> and Exchange Commission directed staff to prepare and is now publishing a report examining the effect and application of the definitions of “<span class=\"match\">security</span>-based swap dealer” and “major <span class=\"match\">security</span>-based swap participant.” Those definitions include an exception from designation as a <span class=\"match\">security</span>-based swap dealer for an entity that engages in a de minimis quantity of <span class=\"match\">security</span>-based swap dealing, as well as separate thresholds below which an entity would not become a major <span class=\"match\">security</span>-based swap participant. As provided"}]}